BPC-157 has 805 independent HPLC tests on this platform and 31 human subjects in the published literature. The vial is far better characterised than the drug, and the most useful sourcing check is one you can run on the vendor's own storage advice.
BPC-157 sits in the tissue repair and healing peptides category. The evidence picture — 175 papers from one laboratory, three uncontrolled human studies, and a Phase 1 trial that never reported — is in BPC-157: where the evidence runs out; this page is about the vial, the label and the law around them. For per-injection volume there is a BPC-157 calculator, or the BPC-157 + TB-500 calculator if you are running both.
What is BPC-157, and why does source quality matter?
BPC-157 is a synthetic 15-amino-acid fragment of Body Protection Compound, CAS 137525-51-0, molecular weight 1419.5 g/mol, cleared in under 30 minutes with no identified dedicated receptor. Source quality matters here in a way specific to the sequence: it contains no methionine, cysteine, tryptophan or tyrosine, so a vendor selling an oxidation-protection storage protocol is describing residues this molecule does not contain. That single tell is readable on the product page before any vial ships.
Property | Value |
|---|---|
Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
Length | 15 amino acids (pentadecapeptide) |
CAS | 137525-51-0 (PubChem CID 9941957) |
Formula / MW | C₆₂H₉₈N₁₆O₂₂ / 1419.5 g/mol |
Half-life | Under 30 minutes; hepatic metabolism, renal clearance |
Receptor | None identified |
Other designations | PL-14736, PLD-116, PL-10, Bepecin |
Read the sequence rather than the marketing. Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val contains none of the classically oxidation-labile residues, and the sequence is independently confirmed in Gwyer et al. (Cell and Tissue Research, 2019) and matches the PubChem record. The phrase "stable gastric pentadecapeptide" that runs through the literature describes resistance to stomach acid — a biological property of the sequence — not shelf stability in a vial.
What is genuinely true about storage is less convenient than the claim it replaces: no peer-reviewed stability or storage study of BPC-157 has been published. Every shelf-life figure in circulation is vendor-derived. General handling practice still applies, as it does for any lyophilised peptide, but nobody can cite a degradation curve for this compound, and a vendor presenting one as measured is presenting a number that does not exist.
The second sourcing risk is that the market has invented a premium version. Pentadeca arginate is sold as an improved BPC-157, and it has its own section below because it changes what you should be checking on the label.
What is the regulatory status of BPC-157?
BPC-157 is not approved for human use and cannot lawfully be compounded as of August 2026. FDA removed it from the 503A Category 2 "do not compound" list in April 2026, and at the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026 the committee voted 8–6 with one abstention to recommend it for the 503A bulks list. That vote is advisory and non-binding, rulemaking is projected for 2027 or later, and nothing has been added. WADA prohibits it at all times under S0.
Because no compounding route exists, this page has no compounded-BPC-157 section — there is no 503A or 503B pathway to compare against research-grade supply, and any pharmacy offering compounded BPC-157 today is operating ahead of a rule that has not been made. See compounding pharmacy versus research peptide for what the distinction normally means and why it does not apply here.
The July 2026 vote is the most misread item in current BPC-157 coverage, and the misreading runs in a predictable direction — a narrow procedural step reported as an approval. Nothing has been added to any list. Compounding BPC-157 is not authorised by that vote, and FDA is not required to follow the recommendation. The full sequence of determinations is in our FDA peptide regulation timeline.
BPC-157 also appears on the Department of Defense prohibited ingredients list. The DoD's Operation Supplement Safety states it plainly: BPC-157 "is not a dietary ingredient. It is an unapproved drug and cannot be legally prescribed or sold over the counter," and "there is little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans."
Claim you will meet while shopping | What the record says | Verdict |
|---|---|---|
"The FDA approved BPC-157 in July 2026" | An 8–6–1 advisory recommendation; no rulemaking completed | False |
"It can be compounded now that it left Category 2" | Removal from Category 2 is not addition to the bulks list | No route exists |
"Clinically proven to heal tendons" | Consistent rodent models; no human musculoskeletal trial | Animal only |
"Human safety is established" | Three uncontrolled studies, ~31 subjects, no controls | No clinical safety data |
"A single 10 mg IV dose is proven safe" | n=2, three days, no controls, no PK curve | Radically overstated |
"Needs cold handling to prevent methionine oxidation" | The sequence contains no methionine | False |
"Pentadeca arginate is the superior form" | Zero peer-reviewed publications exist | Vendor claim only |
"Legal to use in competition" | Prohibited at all times under WADA S0 | No |
"805 clean lab tests mean it works" | Purity is not efficacy, dosing or safety | Category error |
Is pentadeca arginate the same as BPC-157?
No published evidence supports pentadeca arginate as a better BPC-157. A PubMed search for the term returns zero results — no publication establishes its identity, pharmacokinetics, bioavailability, stability advantage or equivalence, and the frequently attached "90% bioavailability" figure has no source. An arginate salt is a counter-ion pairing, not a sequence change, and BPC-157's own sequence contains no arginine. It is marketed as an upgrade, which makes it a labelling question rather than an evidence question.
Axis | BPC-157 | Pentadeca arginate |
|---|---|---|
Peer-reviewed publications | 175 records for the originating author alone | Zero |
Human studies | 3, uncontrolled, ~31 subjects total | None |
Published pharmacokinetics | None in humans | None in any species |
Bioavailability data | Rodent only | "90%" claimed, no source |
Chemical difference | The peptide itself | A counter-ion, not a sequence change |
Independent test data | 588 recency-weighted tests, 23 labs | Not separately indexed |
The practical consequence for a buyer is narrow and specific. Every source describing pentadeca arginate is a vendor, clinic or telehealth page, and the compound is not separately indexed in this platform's test data — so the 588-test purity record behind BPC-157 does not transfer to it. Paying a premium for the arginate version means paying more for a product with no independent analytical dataset and no literature, on the strength of a bioavailability number nobody has published.
The pentadeca arginate compound page tracks it. The evidence base for the differentiating claims is currently empty, which is a different statement from saying the compound does not exist or does not work — nobody has looked.
7 things to check before ordering BPC-157
Seven checks cover BPC-157, and two of them are about the vendor rather than the vial. Mass spectrometry at 1419.5 Da, HPLC read against this platform's 99.35% average across 805 tests, a net peptide content figure, an LAL endotoxin result, the storage rationale printed on the product page, the word "arginate" on the label, and an honest account of what none of it establishes — because the human record is three uncontrolled studies totalling about 31 subjects.
Mass spectrometry at a mass near 1419.5 Da. This is the only check that confirms identity. HPLC reports what proportion of the contents is a single species, not which species — so a certificate showing 99% and no mass result has told you the vial is mostly one thing without telling you what that thing is. Insist on a batch-matched result rather than a specimen certificate from an earlier lot. See mass spectrometry for peptides.
HPLC purity read against BPC-157's own benchmark. This platform records 99.35% across 805 tests and a recency-weighted purity index of 99.37 from 588 tests across 23 laboratories, against a platform composite of 99.50. BPC-157 sits slightly below the composite, which makes "above 98%" a meaningless promise on this compound — the market clears far higher than that routinely.
Net peptide content, stated separately from purity. A 99% pure vial can be substantially underfilled, because purity and quantity are different axes. The purity index deliberately excludes net-content-only tests, so a strong index figure carries no fill information at all. Ask for a net content or amino acid analysis number — why 10 mg isn't 10 mg covers the arithmetic.
An LAL endotoxin result on injectable material. Endotoxin is a pyrogen question that purity testing does not touch. An absent result means the batch was not tested, not that it passed. Peptide endotoxin testing and LAL interpretation covers how to read one.
The storage rationale on the vendor's own page — the BPC-157 competence test. If the page explains that BPC-157 needs particular handling to prevent methionine oxidation, the vendor is describing a residue this molecule does not contain. The sequence has no methionine, no cysteine, no tryptophan and no tyrosine. This is the cheapest quality signal available on this compound, it costs nothing to check, and it tells you whether anyone at the company has read the sequence.
Any shelf-life or expiry figure, read as a claim rather than a specification. No peer-reviewed stability or storage study of BPC-157 has been published. Every shelf-life number in circulation is vendor-derived, so a specific expiry presented as measured is presented on evidence that does not exist. Red flags in peptide certificates of analysis covers documents that assert more than they show.
What no certificate can establish. A perfect CoA confirms that a vendor shipped the correct molecule at the stated quantity. It says nothing about whether BPC-157 works in people, because the entire human record is three uncontrolled studies of roughly 31 subjects, across three unrelated conditions, none randomised, controlled or blinded — and the one registered trial, NCT02637284, a Phase 1 in 42 healthy volunteers estimated to complete in February 2016, never reported a result. There is no human pharmacokinetic data at all.
Check | What it confirms | How to verify | Red flag |
|---|---|---|---|
Mass spectrometry | It is BPC-157 — mass near 1419.5 Da, formula C₆₂H₉₈N₁₆O₂₂ | Batch-matched CoA showing the MS result | Purity reported with no identity test |
Storage rationale on the product page | Whether the vendor has read the sequence | Sequence contains no methionine, cysteine, tryptophan or tyrosine | A handling protocol built on "methionine oxidation" |
The word "arginate" on the label | You are buying BPC-157, not the unindexed premium version | CAS 137525-51-0; the 15-residue sequence | Pentadeca arginate sold as an upgrade — zero publications |
HPLC purity | Proportion of intended peptide | Third-party CoA from a named lab | Below the 99.35% average across 805 tests; vendor's own document only |
Net peptide content | Actual peptide mass versus salts and water | Net content or amino acid analysis figure | Purity quoted as though it were quantity |
Endotoxin (LAL) | No pyrogens in injectable material | LAL result on the batch | Not tested, not mentioned |
Stated shelf life | Nothing, on this compound | No published stability study exists | Any specific expiry presented as measured |
There is a documented precedent for why this is not paranoia. Research-grade custom peptides from two independent commercial suppliers were found to carry contaminating peptides at roughly 1% by weight — enough to produce false-positive results in immunology assays, with a correlation of r²=0.90 between responses to the contaminated peptide and to the contaminant (Clinical and Vaccine Immunology, 2008). That study concerned HIV vaccine peptide libraries rather than BPC-157, but it establishes that reputable suppliers ship contaminated material at levels that change outcomes.
Where does BPC-157 rank on Peptigrity's lab test database?
Peptigrity's Purity Index records a BPC-157 purity index of 99.37 across 588 recency-weighted tests from 23 laboratories (verified August 2026), against a platform composite of 99.50. The BPC-157 compound page shows 805 total HPLC tests averaging 99.35% across 230 verified shops (verified August 2026). The larger figure is larger because the index applies recency weighting and excludes blend vials and net-content-only tests.
Both carry the same caveat, and it is worth stating rather than burying: these are certificates that vendors chose to publish, which is a selection-biased sample rather than a random market survey. It remains the largest analytical dataset on BPC-157 that exists, because there is no published product-testing study to compare it against. Individual results are searchable in the lab test database, and the 23 laboratories behind them differ in method and in how much of the raw trace they publish.
BPC-157 price data shows 66 shops in stock, a median of $5.90/mg and a lowest tracked price of $1.50/mg on a 10 mg vial (verified August 2026). The lowest figure is the lowest of tracked sources, not the lowest payable.
Price measure | Figure (verified August 2026) |
|---|---|
Shops in stock | 66 |
Median | $5.90/mg |
Lowest tracked | $1.50/mg, on a 10 mg vial |
Spread, lowest to median | Roughly 3.9× (our calculation from the two figures above) |
Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. Read the spread within a single vial-size band rather than across the market, since fixed per-vial costs push the per-milligram figure down as fill size rises. Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), and trust scores weight community reviews and independently verified HPLC purity equally at 50% each, with no financial relationship influencing the ranking.
The trial that would settle this is not a testing study. On BPC-157 the supply side is the part that has been measured, across 805 certificates, and the clinical side is the part that has not.
Element | Status |
|---|---|
Human pharmacokinetics | None exists — dosing is extrapolated from rodents |
The only registered trial | NCT02637284, Phase 1, est. 42 subjects, status Unknown, no results posted |
Randomised controlled evidence | None — the three human studies have no control, placebo or blinding |
Human musculoskeletal trial | None, in any tissue |
Published stability or storage study | None — every shelf-life figure is vendor-derived |
Product used in any study | Not the characterised, batch-tested material the market sells |
Until something like that reports, the independent reviewers' conclusion stands. As the 2025 Current Reviews in Musculoskeletal Medicine scoping review put it: "Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution."
Frequently Asked Questions
What purity standard should BPC-157 meet?
Read it against BPC-157's own record rather than a generic threshold. This platform's recency-weighted purity index for BPC-157 is 99.37 across 588 tests from 23 laboratories, and the compound page averages 99.35% across 805 tests. Against a market clearing that high, a vendor promising "above 98%" is promising less than the norm.
How much does BPC-157 cost?
Price data shows 66 shops in stock, a median of $5.90/mg and a lowest tracked price of $1.50/mg on a 10 mg vial (verified August 2026). By our calculation that is close to a fourfold spread, and much of it is vial size rather than quality, since fixed per-vial costs fall away as fill increases.
Is BPC-157 legal now that the FDA advisory committee backed it?
No. The July 2026 vote was a non-binding recommendation, carried 8–6 with one abstention. FDA must complete rulemaking before BPC-157 could be legally compounded, projected for 2027 or later. It remains an unapproved drug and is prohibited in sport at all times under WADA's S0 category.
How do you verify a BPC-157 vial is genuine?
Mass spectrometry showing a mass near 1419.5 Da, on a certificate matched to your batch. HPLC purity alone cannot confirm identity — it only reports what proportion of the contents is a single species, not which species it is. Check the CAS as well: 137525-51-0.
Does stacking BPC-157 with TB-500 change what you should verify?
Yes, in one specific way: each component needs its own identity result, because a mass spectrum confirming one molecule says nothing about the other. Blend vials are also excluded from the purity index, so a blend carries no index figure. See comparing BPC-157 and TB-500.
Do I need to worry about oxidation when storing it?
Not for the reason usually given — BPC-157 contains no methionine, cysteine, tryptophan or tyrosine. Handle it as you would any lyophilised peptide, but be aware that no published stability study for this compound exists, so any specific shelf-life figure you are quoted comes from the seller rather than from measurement.
Browse the tissue repair and healing peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the BPC-157 calculator — or the BPC-157 + TB-500 calculator if you are running both — alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
